Onvitrelin ucalontide

Modify Date: 2024-02-04 05:37:01

Onvitrelin ucalontide Structure
Onvitrelin ucalontide structure
Common Name Onvitrelin ucalontide
CAS Number 1174415-90-7 Molecular Weight 3316.94
Density N/A Boiling Point N/A
Molecular Formula C163H243N43O32 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Onvitrelin ucalontide


Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model[1][2].

 Names

Name Onvitrelin ucalontide

 Onvitrelin ucalontide Biological Activity

Description Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model[1][2].
Related Catalog
References

[1]. Leuschner Carola, et al. Lytic domain fusion constructs and methods of making and using same for treating cell proliferation disorders: World Intellectual Property Organization, WO2009094634. 2009-07-30.

[2]. WHO Drug Information-World Health Organization (WHO).

 Chemical & Physical Properties

Molecular Formula C163H243N43O32
Molecular Weight 3316.94